Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
Retrieved on:
Tuesday, April 11, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., 23andMe, Genetics, Sickle cell trait, American Heart Association, National Science Foundation, SCFG, SCD, Health equity, MSM, Research, CVD, National Institutes of Health, Black, Bangladesh Technical Education Board, Morehouse School of Medicine, Student, National Football League Players Association, Apple Corps, Anti-transglutaminase antibodies, Hemoglobin subunit beta, SCT, Sickle cell disease, Genetic testing, Faculty, Health, FDA, HBB, African Americans, Mobile phone, Nursing, Pharmaceutical industry, UnitedHealth Group
ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status Awareness program to help increase access to sickle cell carrier status information, raise awareness of sickle cell disease (SCD), and offer resources for individuals with sickle cell trait (SCT) and SCD.
Key Points:
- Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease
ATLANTA and SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status Awareness program to help increase access to sickle cell carrier status information, raise awareness of sickle cell disease (SCD), and offer resources for individuals with sickle cell trait (SCT) and SCD. - This includes genetic reports on several conditions that disproportionately affect the Black and African American community, including a Carrier Status report on sickle cell anemia*.
- Program participants will also be offered counseling by the Sickle Cell Foundation of Georgia after receiving their 23andMe results.
- 23andMe’s FDA-authorized Sickle Cell Anemia Carrier Status report tests for the HbS variant in the Hemoglobin Subunit Beta (HBB) gene, which is linked to sickle cell anemia and other forms of SCD.